IS4970A - Setnar 6,6-heteró-bísýklískar afleiður - Google Patents

Setnar 6,6-heteró-bísýklískar afleiður

Info

Publication number: IS4970A
Authority: IS; Iceland
Prior art keywords: hetero; determines; bicyclic derivatives; bicyclic; derivatives
Prior art date: 1996-08-27

Application number

IS4970A

Other languages

English (en)

Inventor

Liang Chen Yuhpyng

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1999-02-05

Publication date

1999-02-05

1999-02-05 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1999-02-05 Publication of IS4970A publication Critical patent/IS4970A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Nutrition Science (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Molecular Biology (AREA)

IS4970A 1996-08-27 1999-02-05 Setnar 6,6-heteró-bísýklískar afleiður IS4970A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2465996P	1996-08-27	1996-08-27
PCT/IB1997/000904 WO1998008846A1 (en)	1996-08-27	1997-07-21	Substituted 6,6-hetero-bicyclic derivatives

Publications (1)

Publication Number	Publication Date
IS4970A true IS4970A (is)	1999-02-05

Family

ID=21821740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4970A IS4970A (is)	1996-08-27	1999-02-05	Setnar 6,6-heteró-bísýklískar afleiður

Country Status (41)

Country	Link
EP (1)	EP0925298B1 (is)
JP (1)	JP2000502722A (is)
KR (1)	KR100457759B1 (is)
CN (2)	CN1191236C (is)
AP (1)	AP1164A (is)
AR (2)	AR009321A1 (is)
AT (1)	ATE264327T1 (is)
AU (1)	AU726771C (is)
BG (1)	BG64316B1 (is)
BR (1)	BR9711262A (is)
CA (1)	CA2263913C (is)
CO (1)	CO4930259A1 (is)
CZ (1)	CZ67799A3 (is)
DE (1)	DE69728676T2 (is)
DK (1)	DK0925298T3 (is)
DZ (1)	DZ2299A1 (is)
EA (1)	EA002607B1 (is)
ES (1)	ES2216157T3 (is)
GT (1)	GT199700093A (is)
HK (1)	HK1019597A1 (is)
HR (1)	HRP970452A2 (is)
ID (1)	ID18189A (is)
IL (1)	IL128049A (is)
IS (1)	IS4970A (is)
MY (1)	MY132671A (is)
NO (1)	NO316273B1 (is)
NZ (1)	NZ333728A (is)
OA (1)	OA10980A (is)
PA (1)	PA8435001A1 (is)
PE (1)	PE108698A1 (is)
PL (1)	PL331988A1 (is)
PT (1)	PT925298E (is)
SI (1)	SI0925298T1 (is)
SK (1)	SK22599A3 (is)
TN (1)	TNSN97144A1 (is)
TR (1)	TR199900408T2 (is)
TW (1)	TW477787B (is)
UA (1)	UA66345C2 (is)
WO (1)	WO1998008846A1 (is)
YU (1)	YU35697A (is)
ZA (1)	ZA977652B (is)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US7094782B1 (en)	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6124289A (en) *	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
JP3345021B2 (ja)	1996-08-06	2002-11-18	ファイザーインク．	置換ピリド―またはピリミド―含有６，６―または６，７―二環式誘導体
WO1998035967A2 (en)	1997-02-18	1998-08-20	Neurocrine Biosciences, Inc.	Biazacyclic crf antagonists
AU7644698A (en)	1997-04-22	1998-11-13	Janssen Pharmaceutica N.V.	Crf antagonistic quino- and quinazolines
NL1010018C2 (nl) *	1997-09-09	1999-03-10	Duphar Int Res	Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
ES2196898T3 (es)	1998-11-12	2003-12-16	Neurocrine Biosciences Inc	Antagonistas de receptores de crf y metodos relacionados.
IL142893A0 (en)	1998-11-12	2002-04-21	Neurocrine Biosciences Inc	Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
WO2000047577A1 (en) *	1999-02-12	2000-08-17	Smithkline Beecham Plc	Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
US6432989B1 (en) *	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
CZ20021086A3 (cs)	1999-09-30	2002-10-16	Neurogen Corporation	Alkylendiaminem substituované heterocykly
BR0014675A (pt)	1999-10-01	2002-07-23	Johnson & Johnson	Processo para acalmar seres humanos utilizando composições de cuidado pessoal
CO5271670A1 (es)	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
US6525067B1 (en) *	1999-11-23	2003-02-25	Pfizer Inc	Substituted heterocyclic derivatives
ATE319103T1 (de)	2000-01-26	2006-03-15	Em Microelectronic Marin Sa	Verfahren zur prüfung einer integrierten schaltung mit vertraulichen software- oder hardware-elementen
EP1293213A1 (en) *	2000-02-14	2003-03-19	Japan Tobacco Inc.	Preventives/remedies for postoperative stress
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1282622B1 (en) *	2000-05-18	2003-09-17	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods relating thereto
MXPA03003612A (es)	2000-10-23	2003-06-19	Smithkline Beecham Corp	Compuestos novedosos.
HUP0304054A2 (hu) *	2001-04-30	2004-04-28	Glaxo Group Limited	A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB0117396D0 (en) *	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
GB2384563A (en)	2002-01-29	2003-07-30	Johnson & Johnson Consumer	Method of measuring the stress or relaxation level of a mammal
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
US7067658B2 (en) *	2002-09-30	2006-06-27	Bristol-Myers Squibb Company	Pyridino and pyrimidino pyrazinones
GEP20084540B (en)	2003-01-14	2008-11-25	Arena Pharm Inc	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0308208D0 (en) *	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
TWI335328B (en)	2003-07-14	2011-01-01	Arena Pharm Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
ATE374190T1 (de)	2003-08-12	2007-10-15	Hoffmann La Roche	Tetrahydrochinazolinderivate als cfr-antagonisten
CA2535249A1 (en)	2003-08-12	2005-02-17	F. Hoffmann-La Roche Ag	Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP2006232849A (ja) *	2003-08-13	2006-09-07	Japan Tobacco Inc	含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
KR20060110006A (ko) *	2004-02-13	2006-10-23	화이자 프로덕츠 인크.	비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물
DE102004018198A1 (de) *	2004-04-15	2005-11-03	Merck Patent Gmbh	Sulfonamide
EP1828186A1 (en)	2004-12-13	2007-09-05	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7423042B2 (en)	2005-03-25	2008-09-09	Glaxo Group Limited	Compounds
PE20100737A1 (es)	2005-03-25	2010-11-27	Glaxo Group Ltd	Nuevos compuestos
TW200724142A (en)	2005-03-25	2007-07-01	Glaxo Group Ltd	Novel compounds
WO2006104917A2 (en)	2005-03-25	2006-10-05	Glaxo Group Limited	Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
CA2602348C (en)	2005-03-31	2011-03-01	Pfizer Products Inc.	Cyclopentapyridine and tetrahydroquinoline derivatives
CN102702194A (zh)	2005-12-21	2012-10-03	雅培制药有限公司	抗病毒化合物
EP1971611B1 (en)	2005-12-21	2012-10-10	Abbott Laboratories	Anti-viral compounds
ATE541844T1 (de)	2005-12-21	2012-02-15	Abbott Lab	Antivirale verbindungen
JP5513118B2 (ja) *	2006-10-19	2014-06-04	シグナルファーマシューティカルズ，エルエルシー	ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
EP2094276A4 (en)	2006-12-20	2011-01-05	Abbott Lab	ANTIVIRAL COMPOUNDS
SI2182950T1 (en) *	2007-05-17	2018-01-31	Helperby Therapeutics Limited	Use of 4- (pyrrolidin-1-yl) quinoline compounds for killing clinically latent microorganisms
WO2011156889A1 (en) *	2010-06-14	2011-12-22	Trt Pharma Inc.	Novel modulators of nrf2 and uses thereof
EP2619198A1 (en)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014029723A1 (en) *	2012-08-24	2014-02-27	F. Hoffmann-La Roche Ag	New bicyclicpyridine derivatives
SI3096756T1 (sl)	2014-01-21	2024-09-30	Neurocrine Biosciences, Inc.	CRF1 receptorski antagonisti za zdravljenje kongenitalne adrenalne hiperplazije
JP6895378B2 (ja)	2015-01-06	2021-06-30	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態の処置方法
AU2016272881C1 (en)	2015-06-04	2019-10-03	Pfizer Inc.	Solid dosage forms of palbociclib
AU2016284162A1 (en)	2015-06-22	2018-02-01	Arena Pharmaceuticals, Inc.	Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
WO2018033815A1 (en)	2016-08-15	2018-02-22	Pfizer Inc.	Pyridopyrimdinone cdk2/4/6 inhibitors
US11168094B2 (en)	2017-01-06	2021-11-09	Azcuris Co., Ltd.	Quinolinone derivative and pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopic dermatitis including the quinolinone derivative as active ingredient
WO2019236757A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
BR112021010847A2 (pt)	2018-12-07	2021-09-08	Neurocrine Biosciences Inc.	Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita
CN115160221B (zh) *	2022-07-26	2024-10-18	恩祺生物科技(上海)有限公司	德立替尼晶型化合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
WO1994013676A1 (en) *	1992-12-17	1994-06-23	Pfizer Inc.	Pyrrolopyrimidines as crf antagonists
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
CN1056611C (zh) *	1994-06-16	2000-09-20	美国辉瑞有限公司	吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
EP0729758A3 (en) *	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
CA2194756A1 (en) *	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
PT778277E (pt) *	1995-12-08	2003-11-28	Pfizer	Derivados heterociclicos substituidos como antagonistas do crf

1997
- 1997-07-15 TW TW086109990A patent/TW477787B/zh not_active IP Right Cessation
- 1997-07-21 DE DE69728676T patent/DE69728676T2/de not_active Expired - Fee Related
- 1997-07-21 ES ES97929464T patent/ES2216157T3/es not_active Expired - Lifetime
- 1997-07-21 CN CNB021020574A patent/CN1191236C/zh not_active Expired - Fee Related
- 1997-07-21 WO PCT/IB1997/000904 patent/WO1998008846A1/en not_active Application Discontinuation
- 1997-07-21 AT AT97929464T patent/ATE264327T1/de not_active IP Right Cessation
- 1997-07-21 NZ NZ333728A patent/NZ333728A/xx unknown
- 1997-07-21 CA CA002263913A patent/CA2263913C/en not_active Expired - Fee Related
- 1997-07-21 EP EP97929464A patent/EP0925298B1/en not_active Expired - Lifetime
- 1997-07-21 AU AU33557/97A patent/AU726771C/en not_active Ceased
- 1997-07-21 JP JP10511427A patent/JP2000502722A/ja active Pending
- 1997-07-21 CZ CZ99677A patent/CZ67799A3/cs unknown
- 1997-07-21 IL IL12804997A patent/IL128049A/en not_active IP Right Cessation
- 1997-07-21 KR KR10-1999-7001619A patent/KR100457759B1/ko not_active IP Right Cessation
- 1997-07-21 SK SK225-99A patent/SK22599A3/sk unknown
- 1997-07-21 EA EA199900166A patent/EA002607B1/ru not_active IP Right Cessation
- 1997-07-21 CN CNB971973555A patent/CN1138774C/zh not_active Expired - Fee Related
- 1997-07-21 DK DK97929464T patent/DK0925298T3/da active
- 1997-07-21 BR BR9711262A patent/BR9711262A/pt not_active Application Discontinuation
- 1997-07-21 SI SI9730642T patent/SI0925298T1/xx unknown
- 1997-07-21 PT PT97929464T patent/PT925298E/pt unknown
- 1997-07-21 PL PL97331988A patent/PL331988A1/xx unknown
- 1997-07-21 UA UA99020647A patent/UA66345C2/uk unknown
- 1997-07-21 TR TR1999/00408T patent/TR199900408T2/xx unknown
- 1997-07-30 PA PA19978435001A patent/PA8435001A1/es unknown
- 1997-08-13 GT GT199700093A patent/GT199700093A/es unknown
- 1997-08-21 AP APAP/P/1997/001076A patent/AP1164A/en active
- 1997-08-22 HR HR60/024,659A patent/HRP970452A2/hr not_active Application Discontinuation
- 1997-08-22 PE PE1997000751A patent/PE108698A1/es not_active Application Discontinuation
- 1997-08-25 ID IDP972952A patent/ID18189A/id unknown
- 1997-08-25 AR ARP970103851A patent/AR009321A1/es not_active Application Discontinuation
- 1997-08-26 CO CO97049282A patent/CO4930259A1/es unknown
- 1997-08-26 YU YU35697A patent/YU35697A/sr unknown
- 1997-08-26 ZA ZA977652A patent/ZA977652B/xx unknown
- 1997-08-26 MY MYPI97003918A patent/MY132671A/en unknown
- 1997-08-26 TN TNTNSN97144A patent/TNSN97144A1/fr unknown
- 1997-08-26 DZ DZ970149A patent/DZ2299A1/fr active
1999
- 1999-02-05 IS IS4970A patent/IS4970A/is unknown
- 1999-02-22 BG BG103192A patent/BG64316B1/bg active Active
- 1999-02-25 OA OA9900039A patent/OA10980A/en unknown
- 1999-02-25 NO NO19990892A patent/NO316273B1/no not_active IP Right Cessation
- 1999-10-25 HK HK99104747A patent/HK1019597A1/xx not_active IP Right Cessation
2001
- 2001-01-10 AR ARP010100097A patent/AR026826A1/es unknown

Also Published As

Publication number	Publication date
BG103192A (en)	1999-09-30
UA66345C2 (en)	2004-05-17
ZA977652B (en)	1999-02-26
HRP970452A2 (en)	1998-08-31
MY132671A (en)	2007-10-31
GT199700093A (es)	1999-02-04
EP0925298B1 (en)	2004-04-14
ES2216157T3 (es)	2004-10-16
AU726771B2 (en)	2000-11-23
AU3355797A (en)	1998-03-19
CN1191236C (zh)	2005-03-02
DZ2299A1 (fr)	2002-12-25
AU726771C (en)	2004-11-11
CA2263913C (en)	2004-06-29
NO990892L (no)	1999-02-25
NO990892D0 (no)	1999-02-25
BG64316B1 (bg)	2004-09-30
IL128049A0 (en)	1999-11-30
OA10980A (en)	2001-11-02
AR026826A1 (es)	2003-02-26
DK0925298T3 (da)	2004-08-09
DE69728676D1 (de)	2004-05-19
SI0925298T1 (en)	2004-08-31
HK1019597A1 (en)	2000-02-18
PL331988A1 (en)	1999-08-16
AP1164A (en)	2003-06-30
TW477787B (en)	2002-03-01
WO1998008846A1 (en)	1998-03-05
EA002607B1 (ru)	2002-06-27
DE69728676T2 (de)	2004-09-30
KR20000035898A (ko)	2000-06-26
PE108698A1 (es)	1999-01-23
AP9701076A0 (en)	1997-10-31
TR199900408T2 (xx)	1999-05-21
CZ67799A3 (cs)	1999-11-17
ATE264327T1 (de)	2004-04-15
TNSN97144A1 (fr)	2005-03-15
CN1138774C (zh)	2004-02-18
NZ333728A (en)	2000-11-24
ID18189A (id)	1998-03-12
SK22599A3 (en)	2000-07-11
NO316273B1 (no)	2004-01-05
AR009321A1 (es)	2000-04-12
EA199900166A1 (ru)	1999-08-26
PT925298E (pt)	2004-07-30
BR9711262A (pt)	1999-08-17
YU35697A (en)	1999-11-22
KR100457759B1 (ko)	2004-11-18
PA8435001A1 (es)	2002-07-30
CO4930259A1 (es)	2000-06-27
CN1228091A (zh)	1999-09-08
JP2000502722A (ja)	2000-03-07
CN1367169A (zh)	2002-09-04
EP0925298A1 (en)	1999-06-30
CA2263913A1 (en)	1998-03-05
IL128049A (en)	2004-12-15

Publication	Publication Date	Title
IS4970A (is)	1999-02-05	Setnar 6,6-heteró-bísýklískar afleiður
DE69736711D1 (de)	2006-11-02	Substituierte 6,5-heterobicyclische-derivate
ATE435861T1 (de)	2009-07-15	12,13-cyclopropan-epothilonderivate
PT901474E (pt)	2006-07-31	Derivados de aril-pirimidina.
NO2006016I1 (no)	2006-11-27	7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt)	2005-01-31	4,5-diaril-imidazoles 2-substituidos
DK1000048T3 (da)	2003-03-03	Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69718771D1 (de)	2003-03-06	Substituierte 1,2,3,4-tetrahydronaphthalinderivate
BR9506532A (pt)	1997-09-16	1,2,3,4,-Tetraidro-5-Nitro-Pirimidinas substituidas
DK0922050T3 (da)	2003-11-24	3-Descladinose-2,3-anhydroerythromycin-derivater
ATE227282T1 (de)	2002-11-15	2,4-diaminopyrimidin-derivate
TR199800988A3 (tr)	1998-12-21	5' Deoksi-Sitidin türevleri.
NO20003825D0 (no)	2000-07-26	1,3,4 - oxadiazolonderivater
DE69714358D1 (de)	2002-09-05	9,10-disubstituierte campothecinderivate mit antitumoraktivität
DE69722064D1 (de)	2003-06-26	1,25-Dihydroxy-16,22,23-trisdehydro-Cholecalciferol-Derivate
TR28915A (tr)	1997-08-06	Naftokinon türevleri.
DK1068200T3 (da)	2005-06-20	2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id)	2000-07-06	Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
NO993024D0 (no)	1999-06-18	Polysakkarid-peptid-derivater
ATE199901T1 (de)	2001-04-15	10,11-dihydro-10-oxo-5h-dibenz(b,f)azepin-5- carboxamidderivate
BR9508248A (pt)	1997-11-04	1,2,4,6-Tiatriazinas herbicidas
BR9510036A (pt)	1997-10-28	Derivados de 1,3,4-oxadiazina
BR9708948A (pt)	1999-08-03	1,3 - Benzodioxois substituídos
TR199700927A3 (tr)	1999-03-22	N-Benzilazolyum türevleri.
ITMI941593A1 (it)	1996-01-27	Tetraidropiridine 3, 3-disostituite